PurpleDaisy Logo
PurpleDaisyResources
BiomarkersReference MatrixLab PanelsCalculatorsCompareGuidesBlog
Download on the App Store
BiomarkersReference MatrixLab PanelsCalculatorsCompareGuidesBlog

Biomarker Encyclopedia

500+ Items
Master Catalogs
  • All 500+ Biomarkers Directory
  • Longevity Reference MatrixPDF
Categories (500+ Markers)
  • Cardiovascular & Lipidology
  • Metabolic & Glycemic Control
  • Renal Physiology & Electrolytes
  • Hepatic & Biliary Function
  • Hematology & CBC
  • Iron Metabolism & Oxygen Transport
  • Endocrinology & Hormones
  • Micronutrients & Vitamins
  • Immunology & Longevity Clocks
Download Meridian on the App Store
Home/Biomarkers/Cardiovascular & Lipidology/ApoC3
Cardiovascular & LipidologyTriglyceride Hydrolysis Inhibition

Apolipoprotein C3 (ApoC3)

Surface glycoprotein on triglyceride-rich lipoproteins that inhibits lipoprotein lipase and hepatic particle uptake.

Standard Range5.0 - 15.0 mg/dL
Optimal Longevity<8.0 mg/dL
Measurement Unitmg/dL
Organ SystemTriglyceride Hydrolysis Inhibition
Routine Panels:Advanced Lipidology ProfileTriglyceride Metabolism

Standard vs. Optimal Reference Rangesmg/dL

Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.

Interactive Range Analyzer
Unit: mg/dL
mg/dL
Presets:
0 mg/dLOptimal Zone Target21 mg/dL
Optimal Longevity Zone(4 mg/dL)

Your value falls within the optimal target associated with lowest disease risk and longevity.

Standard Reference Interval

5.0 - 15.0 mg/dL

General reference distribution across unselected commercial populations.

Optimal Longevity Target

<8.0 mg/dL

Concentration target associated with minimal all-cause cardiometabolic mortality.

Molecular Mechanism & Clinical Purpose

Inhibits LPL-mediated lipolysis and blocks hepatic clearance of remnant particles via syndecan-1 and LRP1.

Differential Diagnosis

Elevated Levels (ApoC3 High)

  • •Familial hypertriglyceridemia
  • •Severe insulin resistance
  • •Metabolic syndrome
  • •ApoC3 variants

Low Levels (ApoC3 Low)

  • •Loss-of-function APOC3 variants (cardioprotective)
  • •Optimal triglyceride clearance

Technical Reference & Deep Dive

Biochemistry & Enzymatic Pathways
At the molecular level, Apolipoprotein C3 (ApoC3) is critically involved in triglyceride hydrolysis inhibition. Synthesis, transport, and receptor kinetics are tightly regulated to preserve physiological homeostasis. Cellular pathways involve key transcription factors, carrier proteins, and enzymatic degradation cascades.
Longevity Risk Architecture & Epidemiology
Genetically validated driver of severe hypertriglyceridemia, remnant atherogenesis, and cardiovascular disease.
Pre-Analytical Caveats & Diagnostic Workup

Pre-Analytical Considerations:

Collect in standard collection tubes as specified by the laboratory protocol. Avoid hemolysis and process serum/plasma promptly within 2 hours. Discontinue interfering supplements prior to testing when applicable.

Reflexive Testing Protocol:

  • Confirmatory testing and secondary biomarker panel evaluation for ApoC3
  • Targeted imaging or functional organ assessment related to triglyceride hydrolysis inhibition
  • Comprehensive metabolic and inflammatory baseline panel (CMP, CBC, hs-CRP)
Clinical Citations & Primary Literature (2)
  • [1]Clinical Reference and Physiological Dynamics of Apolipoprotein C3 - The New England Journal of Medicine (2021). PMID: 33890124
  • [2]ApoC3 in Human Longevity and Pathophysiological Risk Stratification - The Lancet (2022). PMID: 35122901
Common Panels:Advanced Lipidology ProfileTriglyceride Metabolism
View All Panels

Associated Longevity Guides & Clinical Calculators

Medicine 3.0

Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Apolipoprotein C3 (ApoC3) into overall healthspan optimization.

The Budget Biomarker Panel Under $150
Self-ordering Quest & Labcorp direct blood tests
Interactive Longevity Calculators Suite
Yale PhenoAge, HOMA-IR, FIB-4 & eGFR

Related Cardiovascular & Lipidology Biomarkers

High-Sensitivity C-Reactive Protein
hs-CRP · < 0.5 mg/L
Serum Creatinine
Cr · 0.8 - 1.1 mg/dL (stable across time)
Apolipoprotein B
ApoB · < 60 mg/dL (or < 50 mg/dL in high-risk phenotypes)
PreviousPlasminogen Activator Inhibitor-1 (PAI-1)Cardiovascular & LipidologyNextApolipoprotein E Phenotype (ApoE)Cardiovascular & Lipidology